PT  - JOURNAL ARTICLE
AU  - Negi, Ruchita
AU  - Shabab, Jonathan
AU  - Esper, Frank
TI  - The RSV roadmap in children: Lessons learned, paths forward
AID  - 10.3949/ccjm.91.s1.04
DP  - 2024 Sep 01
TA  - Cleveland Clinic Journal of Medicine
PG  - S19--S25
VI  - 91
IP  - 9 suppl 1
4099  - http://www.ccjm.org/content/91/9_suppl_1/S19.short
4100  - http://www.ccjm.org/content/91/9_suppl_1/S19.full
SO  - Cleve Clin J Med2024 Sep 01; 91
AB  - Respiratory syncytial virus (RSV) is a threat to infants globally causing bronchiolitis and pneumonia. Despite decades of research, RSV outbreaks occur with only modest advancements in prevention or treatment. Vaccine development faced challenges because past attempts caused enhanced disease and treatment options demonstrated limited efficacy. Recent advancements, including maternal vaccines focusing on the prefusion form of the F glycoprotein are now showing significant benefits in preventing severe RSV-related illness in infants. Additionally, monoclonal antibodies offer prevention directly to newborns within 1 week of birth. These innovations have the potential to substantially change the impact of RSV.